News

Filter

1 to 9 of 51 results

Baxter says record 2014 results set solid foundation for planned separation

29-01-2015

US drugmaker Baxter International today announced fourth quarter 2014 financial results that exceeded…

Baxter InternationalFinancialPharmaceutical

Plasma fractionation market forecasts to 2019

06-01-2015

The global plasma fractionation market is witnessing continuous growth. The rise in aging population…

Baxter InternationalBio Product LaboratoryBiotestCSL LtdGlobalGrifolsHematologyKedrionLFB BiotechnologiesMarkets & MarketingOctapharmaPharmaceuticalSanquin

FDA approves Baxter’s new treatment for rare form of hemophilia

FDA approves Baxter’s new treatment for rare form of hemophilia

25-10-2014

The US Food and Drug Administration on Friday approved Obizur (antihemophilic Factor [recombinant), porcine…

Baxter InternationalHematologyObizurPharmaceuticalRare diseasesUSA

Baxter third-qtr earnings hit by costs, but sales rise

16-10-2014

US health care product company Baxter International today reported a 14% drop in net income of $468 million…

Baxter InternationalFinancialPharmaceutical

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

21-08-2014

US drugmaker Baxter International has announced positive results from its Phase III pivotal clinical…

AdvateBAX 855Baxter InternationalHematologyPharmaceuticalRegulationResearch

Pfizer spends $635 million on acquiring two Baxter vaccines

Pfizer spends $635 million on acquiring two Baxter vaccines

30-07-2014

US pharma giant Pfizer has entered into a definitive agreement to acquire Baxter International portfolio…

Baxter InternationalMergers & AcquisitionsPfizerPharmaceuticalProductionUSAVaccines

Baxter exceeds own predictions in 2nd-quarter

Baxter exceeds own predictions in 2nd-quarter

17-07-2014

US drugmaker Baxter International reported strong growth across its global franchises in the second quarter…

Baxter InternationalFinancialFundamental analysisPharmaceuticalUSAValuation

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

17-04-2014

US health care company Baxter International as released encouraging top-line results from a Phase III…

BAX 111Baxter InternationalHematologyPharmaceuticalResearch

1 to 9 of 51 results

Back to top